DOCSLIB.ORG

WE WANT to HEAR from YOU Abarca Created the Drug Intelligence Newsletter to Keep Our Clients and Partners Apprised of Critical and Impending Changes to Patient Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WE WANT to HEAR from YOU Abarca Created the Drug Intelligence Newsletter to Keep Our Clients and Partners Apprised of Critical and Impending Changes to Patient Care April 2019 WE WANT TO HEAR FROM YOU Abarca created the Drug Intelligence Newsletter to keep our clients and partners apprised of critical and impending changes to patient care. If there are any topics that you would like to learn more about, or feedback for our Clinical Team, please contact David Capó, Clinical Epidemiologist, at [email protected]. CLINICAL UPDATES, OUTCOMES, & REAL-WORLD EVIDENCE New Pulmonary Arterial Hypertension (PAH) Guidelines Rollout | ACCP In March, the American College of Chest Physicians (ACCP) published an update of the CHEST Guideline and Expert Panel Report on Therapy for Pulmonary Arterial Hypertension (PAH) in Adults[1]. Highlights from the updates include: 1. ACCP now suggests prescribing an initial Letairis™ (ambrisentan; Gilead) and Adcirca™ (tadalafil, currently available as a generic) combination to improve 6-min walk distance (6MWD) in treatment- naive World Health Organization (WHO) functional class (FC) II and III PAH; and to add Adcirca™ to improve 6MWD among stable or symptomatic PAH patients on background Letairis™ 2. Incorporating palliative care services in the management of PAH patients 3. A revamped, evidence-based, and consensus-driven, treatment algorithm to guide the clinician through an organized approach to PAH management (below) PAH Combination Therapy Algorithm Combination therapy with ambrisentan and tadalfil (Recommendation 10; weak Yes recommendation, moderate quality evidence) Treatment Naïve PAH Is the patient willing or able to patients with WHO FC II tolerate combination therapy*? No Monotherapy with either bosentan, macitentan, ambrisentan, riociguat, sildenafil, or tadalafil Combination therapy with ambrisentan and tadalfil (Recommendation 10; weak Treatment Naïve PAH Yes recommendation, moderate quality evidence) patients with WHO FC II Is the patient willing or able to without evidence of rapid tolerate combination therapy*? disease progression or poor prognosis No Monotherapy with either bosentan, macitentan, ambrisentan, riociguat, sildenafil, or tadalafil Chronic Obstructive Pulmonary Disease (COPD) Updated Guidelines | GOLD The Global Initiative for Chronic Obstructive Lung Disease (GOLD) updated their Chronic Obstructive Pulmonary Disease (COPD) Clinical Practice Guidelines[2] in October of 2018. The highlights include: 1. A combination long-acting beta-agonists (LABA)/long‐acting muscarinic antagonist (LAMA) has the greatest quality of life improvement compared to placebo or its individual bronchodilator components. 2. In advanced COPD, fixed triple therapy Trelegy Ellipta™ (umeclidinium-vilanterol-fluticasone; GSK) has forced expiratory volume in one second (FEV1) and exacerbations’ benefits compared to Spiriva™ (tiotropium; Boehringer) or inhaled corticosteroids (ICS)/ LABA combination therapy. 3. Daliresp™ (roflumilast; AstraZeneca) is more useful after a hospitalization for an acute exacerbation. 4. If prone to exacerbations, azithromycin or erythromycin treatment for one year can reduce the risk of recurrence. Initial Treatment in Stable COPD Group C Group D • • ≥ 2 moderate LAMA LAMA • LAMA – long-acting exacerbations or • muscarinic antagonist ≥ 1 leading to LABA + LAMA • LABA – long-acting beta hospitalization • agonist LABA + ICS • ICS – inhaled corticosteroid • mMRC – modified Group A Group C Medical Research Council dyspnea 0 or 1 moderate A long acting questionnaire exacerbations A bronchodilator bronchodilator • CAT – COPD (not leading to Assessment Test hospitalization) LABA LAMA mMRC 0-1 CAT <10 mMRC ≥ 2 CAT ≥ 10 Adapted from MirzaS (2018) COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. Oct; 93 (10): 1488-1502 2 [3] HAVE YOU MET THE NEW MEDS ON THE BLOCK? | JAN – MAR 2019 2019 Manufactur Drug Approva Category For the treatment of: er l New Drugs Approved Excessive sleepiness in adult patients Sunosi™ (solriamfetol) Tab Jazz Pharma 20-Mar Selective DNRI with narcolepsy or OSA Sage Positive allosteric modulator Zulresso™ (brexanolone) IV 19-Mar Postpartum depression Therapeutics of GABAA receptor. Rocklatan™ (netarsudil- Rho kinase inhibitor + Elevated IOP in patients with open- Aerie Pharma 12-Mar latanoprost) Ophthalmic Solution Prostaglandin analog angle glaucoma or ocular hypertension Trazimera™ (trastuzumab- HER-2/ Neu receptor HER-2+ breast cancer, metastatic Pfizer 11-Mar qyyp) IV [Herceptin’s biosimilar] antagonist gastric & GEJ adenocarcinoma Spravato™ (esketamine) Nasal Adults with treatment-resistant Janssen 5-Mar NMDA receptor antagonist Spray depression Herceptin Hylecta™ HER-2/ Neu antagonist + Genentech 28-Feb HER-2 overexpressing breast cancer (trastuzumab-hyaluronidase) SC Recombinant hyaluronidase Adhansia XR™ Adlon ADHD in patients aged 6 years and 27-Feb CNS stimulant (methylphenidate) Caps Therapeutics older Esperoct™ (turoctocog alfa) IV Novo Nordisk 19-Feb Factor VIII molecule Adults and children with hemophilia A Egaten™ (triclabendazole) Tabs Novartis 13-Feb Benzimidazole anthelmintic Fascioliasis by liver flukes vWF directed antibody Adults with aTTP. Combined + plasma Cablivi™ (caplacizumab) IV Ablynx NV 6-Feb fragment exchange & immunosuppression Jeuveau™ (prabotulinumtoxin Purified type A botulinum Temporary improvement of moderate- Evolus 1-Feb A) IM toxin to-severe glabellar “frown” lines Wixela Inhub™ (fluticasone- Mylan 31-Jan Corticosteroid + LABA Asthma and COPD salmeterol) Inhalation Powder Gloperba™ (colchicine) Solution Romeg 30-Jan Uricosuric agent Prophylaxis of gout flares in adults Tosymra™ (sumatriptan) Spray Dr Reddy Labs 25-Jan Serotonin receptor agonist Acute migraine in adults Ontruzant™ (trastuzumab-dttb) Samsung HER-2/ Neu receptor HER-2+ breast cancer, metastatic 18-Jan IV [Herceptin’s biosimilar] Bioepis antagonist gastric & GEJ adenocarcinoma New Indications Advanced TCC, metastatic NSCLC, Tecentriq™ (atezolizumab) IV Genentech 18-Mar PD-L1 blocking antibody combined with Abraxane™ for metastatic triple-negative breast cancer Avycaz™ (avibactam- β-lactamase inhibitor + 3rd HABP, VABP, cIAI, cUTI including Allergan 14-Mar ceftazidime) IV generation cephalosporin pediatric patients 3 months and older Moderate-to-severe atopic dermatitis in Sanofi + IL-4 receptor alpha Dupixent™ (dupilumab) SC 11-Mar adolescents, and add-on maintenance Regeneron antagonist for moderate-to-severe asthma Adults with type 2 diabetes Soliqua 100/33™ (glargine- Long acting insulin + GLP-1 Sanofi 27-Feb uncontrolled on oral antidiabetic lixisenatide) SC agonist therapy Lonsurf™ (tipiracil-trifluridine) Taiho Thymidine phosphorylase + Previously treated metastatic colorectal 22-Feb Caps Oncology Nucleoside inhibitor and gastric & GEJ adenocarcinoma NSCLC, HNSCC, Hodgkins, PMBL, TCC, Human PD-1 blocking Keytruda™ (pembrolizumab) IV Merck 15-Feb HCC, MCC, MSI-H, Gastric, Cervical antibody cancer and adjuvant in melanoma MCL, WM, SLL, MZL, chronic GvHD, and Imbruvica™ (ibrutinib) Tabs Janssen 28-Jan BTK inhibitor treatment-naïve CLL with Gazyva IV Vulvar and vaginal atrophy due to Osphena™ (ospemifene) Tabs Duchesnay 25-Jan Estrogen agonist/ antagonist menopause, including dyspareunia and moderate-to-severe vaginal dryness Fluzone Quadrivalent™ Inactivated influenza virus Influenza immunization, 0.5 mL dose Sanofi 23-Jan (influenza vaccine) IM vaccine approved in children aged ≥ 6 months Abbreviations: ADHD, Attention-deficit/ hyperactivity disorder; aTTP, Acquired thrombotic thrombocytopenic purpura; BTK, Bruton’s tyrosine kinase; cIAI, Complicated intra-abdominal infections; CLL, Chronic lymphocytic leukemia; CNS, Central nervous system; COPD, Chronic obstructive pulmonary disease; cUTI, Complicated urinary tract infections; DNRI, Dopamine & norepinephrine reuptake inhibitor; GABAA, Gamma-aminobutyric acid A; GEJ, Gastroesophageal junction; GLP-1, Glucagon-like peptide-1; GvHD, Graft versus host disease; HABP, Hospital-acquired bacterial pneumonia; HCC, Hepatocellular carcinoma; HER-2+, Human epidermal growth factor receptor positive; HNSCC, Head & neck squamous cell carcinoma; IL-4, Interleukin-4; IM, Intramuscular; IOP, Intraocular pressure; IV, Intravenous; LABA, Long-acting beta2-adrenergic agonist; MCC, Merkel cell carcinoma; MCL, Mantle cell lymphoma; MSI-H, Microsatellite instability-high cancer; MZL, Marginal zone lymphoma; NMDA, Non-competitive N-methyl D-aspartate; NSCLC, Non-small cell lung cancer; OSA, Obstructive sleep apnea; PD-1, Programmed death receptor-1; PD-L1, Programmed death- ligand 1; PMBL, Primary mediastinal large B-cell lymphoma; SC, Subcutaneous; SLL, small lymphocytic lymphoma; TCC-UC, Transitional cell carcinoma/ Urothelial carcinoma; VABP, Ventilator-associated bacterial pneumonia; vWF, Von Willebrand factor; WM, Waldenström’s macroglobulinemia. 3 SEEING OPPORTUNITY READY FOR THESE HIGHLY ANTICIPATED DRUGS? Treatment-Resistant Depression (TRD) Up to 7% of US adults experience at least one major depressive disorder (MDD) episode each year. Treatment- resistant depression (TRD) refers to failure of at least 2 trials of antidepressant monotherapies, and affects approximately one in three patients with depression. TRD treatments include upgrading antidepressants or augmenting existing prescriptions with non-antidepressant medications (such as atypical antipsychotics). Among those with TRD, there are patients with refractory depression--showing symptoms over long periods of time, multiple relapses, and many sequential treatment regimens with inadequate responses. For these highly resistant and difficult to treat patients, electroconvulsive therapy (ECT) and transcranial
Load more

Recommended publications
  • Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study
    International Journal of Environmental Research and Public Health Article Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study Hsin-Chien Chen 1,* , Chih-Hung Wang 1,2 , Wu-Chien Chien 3,4 , Chi-Hsiang Chung 3,4, Cheng-Ping Shih 1, Yi-Chun Lin 1,2, I-Hsun Li 5,6, Yuan-Yung Lin 1,2 and Chao-Yin Kuo 1 1 Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (C.-H.W.); [email protected] (C.-P.S.); [email protected] (Y.-C.L.); [email protected] (Y.-Y.L.); [email protected] (C.-Y.K.) 2 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan 3 School of Public Health, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (W.-C.C.); [email protected] (C.-H.C.) 4 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 5 Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] 6 School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan * Correspondence: [email protected]; Tel.: +886-2-8792-7192; Fax: +886-2-8792-7193 Received: 31 July 2020; Accepted: 28 August 2020; Published: 31 August 2020 Abstract: The effect of dextromethorphan (DXM) use in sensorineural hearing loss (SNHL) has not been fully examined. We conducted an animal model and nationwide retrospective matched-cohort study to explore the association between DXM use and SNHL.
    [Show full text]
  • Hallucinogens
    Hallucinogens What are hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their own thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and some are synthetic (human- made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes, including to have fun, deal with stress, have spiritual experiences, or just to feel different. Common classic hallucinogens include the following: • LSD (D-lysergic acid diethylamide) is one of the most powerful mind-altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other grains. LSD has many other street names, including acid, blotter acid, dots, and mellow yellow. • Psilocybin (4-phosphoryloxy-N,N- dimethyltryptamine) comes from certain types of mushrooms found in tropical and subtropical regions of South America, Mexico, and the United States. Some common names for Blotter sheet of LSD-soaked paper squares that users psilocybin include little smoke, magic put in their mouths. mushrooms, and shrooms. Photo by © DEA • Peyote (mescaline) is a small, spineless cactus with mescaline as its main ingredient. Peyote can also be synthetic.
    [Show full text]
  • Antidepressant & Psychedelic Drug Interaction Chart
    Copyright Psychedelic School 8/2020 Antidepressant & Psychedelic Drug Interaction Chart This chart is not intended to be used to make medical decisions and is for informational purposes only. It was constructed using data whenever possible, although extrapolation from known information was also used to inform risk. Any decision to start, stop, or taper medication and/or use psychedelic drugs should be made in conjunction with your healthcare provider(s). It is recommended to not perform any illicit activity. This chart the intellectual property of psychedelic school and is for personal use only. Please do not copy or distribute this chart. Antidepressant Phenethylamines Tryptamines MAOI-containing Ketamine Ibogaine -MDMA, mescaline -Psilocybin, LSD -Ayahuasca, Syrian Rue SSRIs Taper & discontinue at least 2 Consider taper & Taper & discontinue at least 2 Has been studied and Taper & discontinue at · Paroxetine (Paxil) weeks prior (all except discontinuation at least 2 weeks weeks prior (all except found effective both with least 2 weeks prior (all · Sertraline (Zoloft) fluoxetine) or 6 weeks prior prior (all except fluoxetine) or 6 fluoxetine) or 6 weeks prior and without concurrent except fluoxetine) or 6 · Citalopram (Celexa) (fluoxetine only) due to loss of weeks prior (fluoxetine only) (fluoxetine only) due to use of antidepressants weeks prior (fluoxetine · Escitalopram (Lexapro) psychedelic effect due to potential loss of potential risk of serotonin only) due to risk of · Fluxoetine (Prozac) psychedelic effect syndrome additive QTc interval · Fluvoxamine (Luvox) MDMA is unable to cause Recommended prolongation, release of serotonin when the Chronic antidepressant use may Life threatening toxicities can to be used in conjunction arrhythmias, or SPARI serotonin reuptake pump is result in down-regulation of occur with these with oral antidepressants cardiotoxicity · Vibryyd (Vilazodone) blocked.
    [Show full text]
  • Janssen Research & Development, LLC Advisory Committee Briefing
    Janssen Research & Development, LLC Advisory Committee Briefing Document Esketamine Nasal Spray for Patients with Treatment-resistant Depression JNJ-54135419 (esketamine) Status: Approved Date: 16 January 2019 Prepared by: Janssen Research & Development, LLC EDMS number: EDMS-ERI-171521650, 1.0 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE 1 Status: Approved, Date: 16 January 2019 JNJ-54135419 (esketamine) Treatment-resistant Depression Advisory Committee Briefing Document GUIDE FOR REVIEWERS This briefing document provides 3 levels of review with increasing levels of detail: The Executive Overview (Section 1, starting on page 11) provides a narrative summarizing the disease, need for novel treatments, key development program characteristics for esketamine nasal spray, study results, and conclusions. References are made to the respective supporting sections in the core document. The core document (Section 2 to Section 11, starting on page 30) includes detailed summaries and discussion in support of the Executive Overview. The appendices (starting on page 180) provide additional or more detailed information to complement brief descriptions provided in sections of the core document (e.g., demographic and baseline characteristics of the study populations, additional efficacy analyses in the Phase 3 studies, statistical methods). These appendices are referenced in the core document when relevant. This review structure allows review at varying levels of detail; however, reviewers who read at multiple levels will necessarily
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • The Effects of Ketamine on Dopaminergic Function: Meta-Analysis and Review of the Implications for Neuropsychiatric Disorders
    OPEN Molecular Psychiatry (2018) 23, 59–69 www.nature.com/mp REVIEW The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders M Kokkinou1,2, AH Ashok1,2,3 and OD Howes1,2,3 Ketamine is a non-competitive antagonist at the N-methyl-D-aspartate receptor. It has recently been found to have antidepressant effects and is a drug of abuse, suggesting it may have dopaminergic effects. To examine the effect of ketamine on the dopamine systems, we carried out a systematic review and meta-analysis of dopamine measures in the rodent, human and primate brain following acute and chronic ketamine administration relative to a drug-free baseline or control condition. Systematic search of PubMed and PsychInfo electronic databases yielded 40 original peer-reviewed studies. There were sufficient rodent studies of the acute effects of ketamine at sub-anaesthetic doses for meta-analysis. Acute ketamine administration in rodents is associated with significantly increased dopamine levels in the cortex (Hedge’s g = 1.33, Po0.01), striatum (Hedge’s g = 0.57, Po0.05) and the nucleus accumbens (Hedge’s g = 1.30, Po0.05) compared to control conditions, and 62–180% increases in dopamine neuron population activity. Sub-analysis indicated elevations were more marked in in vivo (g = 1.93) than ex vivo (g = 0.50) studies. There were not enough studies for meta-analysis in other brain regions studied (hippocampus, ventral pallidum and cerebellum), or of the effects of chronic ketamine administration, although consistent increases in cortical dopamine levels (from 88 to 180%) were reported in the latter studies.
    [Show full text]
  • Rxoutlook® 1St Quarter 2019
    ® RxOutlook 1st Quarter 2020 optum.com/optumrx a RxOutlook 1st Quarter 2020 Orphan drugs continue to feature prominently in the drug development pipeline In 1983 the Orphan Drug Act was signed into law. Thirty seven years later, what was initially envisioned as a minor category of drugs has become a major part of the drug development pipeline. The Orphan Drug Act was passed by the United States Congress in 1983 in order to spur drug development for rare conditions with high unmet need. The legislation provided financial incentives to manufacturers if they could demonstrate that the target population for their drug consisted of fewer than 200,000 persons in the United States, or that there was no reasonable expectation that commercial sales would be sufficient to recoup the developmental costs associated with the drug. These “Orphan Drug” approvals have become increasingly common over the last two decades. In 2000, two of the 27 (7%) new drugs approved by the FDA had Orphan Designation, whereas in 2019, 20 of the 48 new drugs (42%) approved by the FDA had Orphan Designation. Since the passage of the Orphan Drug Act, 37 years ago, additional regulations and FDA designations have been implemented in an attempt to further expedite drug development for certain serious and life threatening conditions. Drugs with a Fast Track designation can use Phase 2 clinical trials to support FDA approval. Drugs with Breakthrough Therapy designation can use alternative clinical trial designs instead of the traditional randomized, double-blind, placebo-controlled trial. Additionally, drugs may be approved via the Accelerated Approval pathway using surrogate endpoints in clinical trials rather than clinical outcomes.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • 094 Esketamine Nasal Spray
    Esketamine Nasal Spray (SpravatoTM) and Intravenous Ketamine for Mental Health Conditions Prior Authorization Request Form Medical Policy #087 Esketamine Nasal Spray (SpravatoTM) and Intravenous Ketamine for Mental Health Conditions Please use this form to assist in identifying members who meet Blue Cross Blue Shield of Massachusetts’ (BCBSMA’s) medical necessity criteria for Esketamine Nasal Spray (SpravatoTM) and Intravenous Ketamine for Treatment-Resistant Depression. For members who do not meet all the criteria listed below, submit a letter of medical necessity with a request for Clinical Exception (Individual Consideration) and include copied of clinical documentation supporting the clinical exception request . Once completed, please fax to: 1-888-641-5199 Patient Information Patient Name: Today’s Date: BCBSMA ID#: Treatment Start Date: Date of Birth: Place of Service: Outpatient Inpatient Physician Information Facility Information Name: Name: Address: Address: Phone #: Phone #: Fax#: Fax#: This is a secure fax line This is a secure fax line NPI / TIN#: NPI / TIN#: For Esketamine and IV Ketamine requests for TREATMENT RESISTANT DEPRESSION: Initial requests are authorized for up to 28 days - Number of treatment session requested: __________________________ Esketamine (Spravato) Nasal Spray: Initial Therapy Intravenous Ketamine: Initial Therapy Individual is 18 or over, Individual meets the (DSM-5) criteria for a major depressive episode (See Table 1 in medical policy #087) by a structured clinical interview for DSM-5 disorders, Current depressive episode is severe depression based on either of the following: a. Montgomery-Asberg Depression Rating Scale (MADRS) ≥ 28 OR b. Hamilton Rating Scale for Depression (HAM-D) score ≥ 17 AND, Individual has had an inadequate response to four antidepressant agents from at least: • Four antidepressant agents from at least: o 2 or more different antidepressant classes (i.e.
    [Show full text]
  • Esketamine (Spravato®) Nasal Spray Restricted Product(S)
    Corporate Medical Policy: Esketamine (Spravato®) Nasal Spray Restricted Product(s): • esketamine (Spravato®) intranasal spray for administration under supervision of healthcare professional FDA Approved Use: • For the treatment of treatment-resistant depression in adults • For the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior • Limitations of use: o Effectiveness in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated; use of Spravato does not preclude need for hospitalization if clinically warranted, even if improvement is observed following initial dosing o Not approved as an anesthetic agent, as safety and effectiveness for this use have not been established Criteria for Medical Necessity: The restricted product(s) may be considered medically necessary when the following criteria are met: Initial Criteria for Approval: 1. The patient is 18 years of age or older; AND 2. The patient has been diagnosed with treatment-resistant depression (TRD); AND a. The patient has a confirmed diagnosis of major depressive disorder (MDD) to include one of the following: i. If single-episode MDD, the duration has been ≥ 2 years; OR ii. Recurrent MDD without psychotic features; AND b. In the current depressive episode, the patient has had an inadequate response (≤ 25% improvement) to at least two different oral antidepressants of adequate dose and duration (typically 6 weeks); OR 3. The patient has been diagnosed with major depressive disorder (MDD) with suicidal ideation or behavior; AND a. The suicidal ideation and intent are imminent and warrant potential hospitalization; AND 4. At initiation of treatment with esketamine nasal spray, the patient has a depression symptom severity of ≥ 28 on the Montgomery-Asberg Depression Rating Scale (MADRS), or as scored by a comparable standardized rating scale that reliably measures depressive symptoms; AND 5.
    [Show full text]
  • Swissmedic Journal 01 2019
    Schweizerisches Heilmittelinstitut Institut suisse des produits thérapeutiques Istituto svizzero per gli agenti terapeutici Swiss Agency for Therapeutic Products Swissmedic Journal 01/2019 18. Jahrgang 18° année ISSN 2234-9456 Amtliches Publikationsorgan der Swissmedic, Schweizerisches Heilmittelinstitut, Bern Publication officielle de Swissmedic, Institut suisse des produits thérapeutiques, Berne Erscheint monatlich/Publication mensuelle www.swissmedic.ch/journal Redaktion und Administration: Swissmedic, Abteilung Kommunikation, Hallerstrasse 7, 3012 Bern Tel. +41 58 462 02 11 Grafische Aufbereitung: Rickli+Wyss AG, Eymattstrasse 5, Postfach 316, 3027 Bern Inhalt / Table des matières Seite Seite Arzneimittel Nachrichten Arzneimittel Statistik Zulassung eines Arzneimittels mit Neuzulassung 6 neuem Wirkstoff: Radicava®, Revision und Änderung der Zulassung 11 Infusionslösung (Edaravonum) 4 Änderung der Zulassungsinhaberin 63 Widerruf der Zulassung 65 Erlöschen der Zulassung 67 Eingang eines vollständigen Gesuchs um Zulassung, um Erweiterung der Indikation oder um Erweiterung der Zulassung eines Arzneimittels 70 Swissmedic Kontaktliste Auf unserer Website www.swissmedic.ch finden Sie unter dem Navigationspunkt «Über uns» in der Rubrik «Kontakt» die Kontaktmaske für Anfragen und Reklamationen. Adressen für Meldungen sowie weitere Adressen finden Sie auf den entsprechenden Themenseiten. Zeichenerklärung Abgabekategorien A Einmalige Abgabe auf ärztliche oder C Abgabe nach Fachberatung durch tierärztliche Verschreibung Medizinalpersonen B Abgabe
    [Show full text]
  • Esketamine for Treatment-Resistant Depression Authors: Bryanna Nicole Tibensky, Louis De Léséleuc, Christine Perras, Lory Picheca
    CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES Informing Decisions About New Health Technologies Issue April 176 2019 Esketamine for Treatment- Resistant Depression Image: Courtesy of Janssen CADTH ISSUES IN EMERGING HEALTH TECHNOLOGIES | Esketamine for Treatment-Resistant Depression Authors: Bryanna Nicole Tibensky, Louis de Léséleuc, Christine Perras, Lory Picheca Cite As: Esketamine for Treatment-Resistant Depression. Ottawa: CADTH; 2019 April. (CADTH issues in emerging health technologies; issue 176). ISSN: 1488-6324 Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy- makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]